Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Mariam Ujeyl"'
Autor:
Wulf Rössler, Mariam Ujeyl, Wolfram Kawohl, Carlos Nordt, Antonio Lasalvia, Helene Haker, Michael P. Hengartner
Publikováno v:
Frontiers in Psychiatry, Vol 10 (2019)
Background: Individual placement and support (IPS) has proven to be effective for vocational outcomes in people with mental illness. The original concept of IPS requires temporally unlimited provision of support. Using limited placement budgets and i
Externí odkaz:
https://doaj.org/article/ad940efa8a8f44dd9aa4a29c144f6822
Autor:
Wulf Rössler, Jules Angst, Vladeta Ajdacic-Gross, Helene Haker, Sofian Berrouiguet, Mariam Ujeyl, Nicholas Glozier, Michael P. Hengartner
Publikováno v:
Frontiers in Psychiatry, Vol 9 (2018)
Study objectives: Associations between sleep problems and suicidality are increasingly acknowledged, but prospective data from well-controlled long-term community studies are lacking.Methods: We analyzed data from a longitudinal cohort study with n =
Externí odkaz:
https://doaj.org/article/c74bdf443bbd4f42a47807b82652d7f9
Autor:
Mariam Ujeyl, Wulf Rössler
Psychosocial rehabilitation (synonymously referred to as psychiatric rehabilitation) is a field and service within mental health systems that shifted the treatment focus from symptom control to social inclusion by functional recovery. It aims to help
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02e67d1cfcd81427cb7f9d3786750083
https://doi.org/10.1093/med/9780198836506.003.0014
https://doi.org/10.1093/med/9780198836506.003.0014
Autor:
Antonio Lasalvia, Michael Pascal Hengartner, Helene Haker, Wolfram Kawohl, Mariam Ujeyl, Carlos Nordt, Wulf Rössler
Publikováno v:
Frontiers in Psychiatry, 10
Frontiers in Psychiatry
Frontiers in Psychiatry, Vol 10 (2019)
Frontiers in Psychiatry
Frontiers in Psychiatry, Vol 10 (2019)
Background: Individual placement and support (IPS) has proven to be effective for vocational outcomes in people with mental illness. The original concept of IPS requires temporally unlimited provision of support. Using limited placement budgets and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75b26ca4f50d3b68d106186504c3c7ac
Autor:
Nick Glozier, Helene Haker, Jules Angst, Michael Pascal Hengartner, Sofian Berrouiguet, Mariam Ujeyl, Wulf Rössler, Vladeta Ajdacic-Gross
Publikováno v:
Frontiers in Psychiatry
Frontiers in Psychiatry, Frontiers, 2018, 9, ⟨10.3389/fpsyt.2018.00320⟩
Frontiers in Psychiatry, Vol 9 (2018)
Frontiers in Psychiatry, 9
Frontiers in Psychiatry, Frontiers, 2018, 9, ⟨10.3389/fpsyt.2018.00320⟩
Frontiers in Psychiatry, Vol 9 (2018)
Frontiers in Psychiatry, 9
Frontiers in Psychiatry, 9
ISSN:1664-0640
ISSN:1664-0640
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df35c90cdb961961c636339c49f0038d
https://doi.org/10.5167/uzh-167273
https://doi.org/10.5167/uzh-167273
Autor:
Thomas Stammschulte, Helmut Schröder, Julian Bleek, Hans Wille, Peter Ihle, Rebecca Hein, Ursula Gundert-Remy, Gerhard Schillinger, Ingrid Schubert, Sebastian Harder, Anette Zawinell, Ingrid Köster, Mariam Ujeyl
Publikováno v:
European journal of clinical pharmacology. 74(10)
The pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF) compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based studies. Comparisons with phenprocoumon, the most frequently used vitamin K ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8dcdc8fefe9af08af451fc8e5bb07f1
https://pubmed.ncbi.nlm.nih.gov/29909576
https://pubmed.ncbi.nlm.nih.gov/29909576
Publikováno v:
Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 107:461-467
Zusammenfassung Hintergrund Bis zum Inkrafttreten des AMNOG konnten die Preise neuer Arzneimittel (NA) frei festgesetzt werden. Unsere Arbeit untersucht beispielhaft, wie sich die Jahrestherapiekosten von NA, die in den zwei Jahren vor Inkrafttreten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::535f9a1feb37f96cc1d34acbb0e87090
https://doi.org/10.1016/j.zefq.2013.04.031
https://doi.org/10.1016/j.zefq.2013.04.031
Publikováno v:
Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. 107(7)
Until AMNOG came into effect Germany had free pricing of new drugs. Our exemplary work investigates the costs of new drugs that were licensed in the two years prior to AMNOG, and compares them to the costs of standard treatment that has been used in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5a0f5f2ac05865232a838c6e30868d15
https://pubmed.ncbi.nlm.nih.gov/24238023
https://pubmed.ncbi.nlm.nih.gov/24238023
Publikováno v:
Deutsches Ärzteblatt international.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::983a3af8490daeb36c2304cff6a0b11c
https://doi.org/10.3238/arztebl.2012.0436b
https://doi.org/10.3238/arztebl.2012.0436b
Publikováno v:
Deutsches Ärzteblatt international.
Drug approval is governed by the criteria quality, efficacy, and safety. In Germany, approval may follow one of the three procedures below: The EU’s Centralized Procedure valid for licensing in all EU member states. A national licensing procedure v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0293dcc5564c866742939ad93b48cbac
https://doi.org/10.3238/arztebl.2012.0117
https://doi.org/10.3238/arztebl.2012.0117